{"id":"polio-sabin","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal symptoms"},{"rate":"null","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This immune response helps the body recognize and fight the poliovirus, providing protection against polio infection. The vaccine is administered orally and contains three different strains of the weakened poliovirus.","oneSentence":"The Polio Sabin vaccine works by introducing a weakened form of the poliovirus to stimulate an immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:33.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Polio prevention"}]},"trialDetails":[{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT05644184","phase":"PHASE2","title":"Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","status":"RECRUITING","sponsor":"PATH","startDate":"2023-03-27","conditions":"Poliomyelitis","enrollment":2232},{"nctId":"NCT05850364","phase":"PHASE3","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-05-22","conditions":"Poliomyelitis, Polio","enrollment":1442},{"nctId":"NCT06331156","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-03-22","conditions":"Gastroenteritis","enrollment":400},{"nctId":"NCT06137664","phase":"PHASE1, PHASE2","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","status":"RECRUITING","sponsor":"PATH","startDate":"2024-11-20","conditions":"Poliomyelitis","enrollment":2400},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT06346834","phase":"PHASE4","title":"Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2024-05-20","conditions":"Poliomyelitis","enrollment":200},{"nctId":"NCT03032588","phase":"PHASE1","title":"A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-10-09","conditions":"Healthy","enrollment":32},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT04529538","phase":"PHASE1","title":"Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-26","conditions":"Poliomyelitis","enrollment":226},{"nctId":"NCT04579510","phase":"PHASE2","title":"Immunogenicity nOPV2 With and Without bOPV","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2021-02-08","conditions":"Poliomyelitis","enrollment":795},{"nctId":"NCT02961595","phase":"PHASE1","title":"Live Enterovirus Vaccine and Type 1 Diabetes","status":"COMPLETED","sponsor":"Tampere University","startDate":"1999-10","conditions":"Enterovirus Infection, Type 1 Diabetes, Prediabetic State","enrollment":315},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT05654467","phase":"PHASE2","title":"Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","status":"UNKNOWN","sponsor":"PATH","startDate":"2023-12-05","conditions":"Poliomyelitis","enrollment":1532},{"nctId":"NCT03564782","phase":"EARLY_PHASE1","title":"Examining Bioactivity of PVSRIPO in Invasive Breast Cancer","status":"COMPLETED","sponsor":"Istari Oncology, Inc.","startDate":"2019-06-30","conditions":"Invasive Breast Cancer","enrollment":5},{"nctId":"NCT05327426","phase":"PHASE1","title":"Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-04-01","conditions":"Poliomyelitis","enrollment":19},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04220515","phase":"PHASE4","title":"Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-02-08","conditions":"Poliomyelitis","enrollment":49731},{"nctId":"NCT01510366","phase":"PHASE3","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-01","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04224519","phase":"PHASE4","title":"Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-04-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT01491893","phase":"PHASE1","title":"PVSRIPO for Recurrent Glioblastoma (GBM)","status":"COMPLETED","sponsor":"Istari Oncology, Inc.","startDate":"2012-04-25","conditions":"GBM, Glioblastoma, Glioma","enrollment":61},{"nctId":"NCT05952596","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-07-17","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT04693286","phase":"PHASE2","title":"Clinical Trial of Novel OPV2 Vaccine","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2020-09-21","conditions":"Poliomyelitis","enrollment":330},{"nctId":"NCT04614597","phase":"","title":"A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2020-10-29","conditions":"Poliomyelitis","enrollment":774},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT04544787","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2018-10-22","conditions":"Poliomyelitis","enrollment":250},{"nctId":"NCT04386707","phase":"PHASE3","title":"Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-05-11","conditions":"Poliomyelitis","enrollment":1300},{"nctId":"NCT03430349","phase":"PHASE1","title":"Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2017-05-16","conditions":"Poliomyelitis","enrollment":30},{"nctId":"NCT04638985","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-13","conditions":"Vaccine","enrollment":600},{"nctId":"NCT00263666","phase":"PHASE2","title":"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-16","conditions":"Infections, Rotavirus","enrollment":100},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT04051736","phase":"PHASE4","title":"Immunogenicity and Safety of Sabin-IPV Replacement Vaccination","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination","enrollment":360},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT03597919","phase":"PHASE4","title":"A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2018-05-28","conditions":"Poliomyelitis","enrollment":560},{"nctId":"NCT02434770","phase":"PHASE3","title":"Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2015-08","conditions":"Poliomyelitis","enrollment":750},{"nctId":"NCT03092791","phase":"PHASE1, PHASE2","title":"IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2017-06-07","conditions":"Poliomyelitis","enrollment":340},{"nctId":"NCT02582255","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-11","conditions":"Poliomyelitis","enrollment":100},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00678301","phase":"PHASE3","title":"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-18","conditions":"Infections, Streptococcal","enrollment":365},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT03147560","phase":"PHASE4","title":"Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2017-05-02","conditions":"Polio","enrollment":528},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03169725","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-05-31","conditions":"Poliomyelitis","enrollment":1417},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT01175083","phase":"PHASE3","title":"Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-01","conditions":"Infections, Streptococcal","enrollment":300},{"nctId":"NCT03902054","phase":"PHASE2","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-12-28","conditions":"Polio and Post-Polio Syndrome","enrollment":600},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03526978","phase":"PHASE3","title":"An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-08-08","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT02985320","phase":"PHASE1, PHASE2","title":"Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2016-10","conditions":"Poliomyelitis","enrollment":708},{"nctId":"NCT01056705","phase":"PHASE2","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2009-07","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01586572","phase":"NA","title":"Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2012-04","conditions":"Polio","enrollment":1000},{"nctId":"NCT01708720","phase":"PHASE1","title":"Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Pauline Verdijk","startDate":"2011-08","conditions":"Poliomyelitis","enrollment":45},{"nctId":"NCT01709071","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Pauline Verdijk","startDate":"2012-02","conditions":"Poliomyelitis","enrollment":140},{"nctId":"NCT01048190","phase":"PHASE1","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2008-08","conditions":"Poliomyelitis","enrollment":130}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"GASTROENTERITIS"},{"count":1,"reaction":"DEHYDRATION"},{"count":1,"reaction":"EYE PRURITUS"},{"count":1,"reaction":"IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME"},{"count":1,"reaction":"IMMUNE RECONSTITUTION SYNDROME"},{"count":1,"reaction":"MALARIA"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"PSEUDOMEMBRANOUS COLITIS"},{"count":1,"reaction":"TACHYPNOEA"},{"count":1,"reaction":"UPPER RESPIRATORY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OPV","Oral Polio vaccine (OPV)."],"phase":"phase_3","status":"active","brandName":"Polio Sabin","genericName":"Polio Sabin","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Polio Sabin vaccine works by introducing a weakened form of the poliovirus to stimulate an immune response. Used for Polio prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}